Coherus Biosciences | CHRS - Pre Tax Profit


Coherus Biosciences reported $-47.4M in Pre-Tax Profit for its fiscal quarter ending in March of 2025.





Pre Tax Profit Change Date
AbbVie USD 4.38B 1.92B Sep/2025
Acadia Pharmaceuticals USD 26.32M 18.28M Dec/2025
Akebia Therapeutics USD 6.11M 28.92M Mar/2025
ALKERMES USD 100.74M 4.1M Sep/2025
Alnylam Pharmaceuticals USD 161.14M 77.83M Dec/2025
Amarin USD -8.12M 5.34M Sep/2025
Amgen USD 3.92B 2.35B Sep/2025
Baxter International USD 121M 12M Sep/2025
Biogen USD 557.3M 186.7M Sep/2025
BioMarin Pharmaceutical USD -26.32M 324.19M Sep/2025
Bristol-Myers Squibb USD 3.11B 1.34B Sep/2025
Coherus Biosciences USD -47.4M 14.9M Mar/2025
Eli Lilly USD 7.23B 456M Sep/2025
Fujifilm JPY 100.28B 10.32B Dec/2025
Gilead Sciences USD 3.64B 1.21B Sep/2025
Ironwood Pharmaceuticals USD 68.02M 30.2M Sep/2025
Merck USD 6.74B 22M Sep/2025
Myriad Genetics USD 6.2M 2.1M Dec/2024
Pacira USD 9.52M 11.45M Sep/2025
Perrigo USD 22.4M 19.2M Sep/2025
Pfizer USD 3.33B 290M Sep/2025
PTC Therapeutics USD -139.08M 116.01M Dec/2025
Regeneron Pharmaceuticals USD 1.76B 244.6M Sep/2025
Sarepta Therapeutics USD -407.67M 213.63M Dec/2025
Teva Pharmaceutical Industries USD 91M 555M Dec/2025
Vertex Pharmaceuticals USD 1.3B 15.8M Sep/2025
Xencor USD -4.27M 1.76M Dec/2025
Zoetis USD 887M 15M Sep/2025